People on the Move
Neuralstem
Neuralstem
Stem cell firm Neuralstem has announced the appointment of Jonathan Lloyd Jones as Chief Financial Officer.
The company uses neural stem cell tech to develop small and large molecule therapies for CNS diseases.
Lloyd Jones has over 25 years of corporate finance and business development experience. Most recently, he served as Chief Financial Officer at Columbia Laboratories (Juniper Pharmaceuticals), and as CFO and VP of Corporate Development at ventutre-backed pharma company TetraLogic.
He has also worked at TransMolecular,Genzyme, Royal Bank of Scotland, and Deloitte.
Neuralstem's first stem cell product candidate, NSI-566, a spinal cord-derived neural stem cell line, has finished Phase II trials for amyotrophic lateral sclerosis (ALS, or motor neuron disease).
